Are you over 18 and want to see adult content?
More Annotations
A complete backup of exams-ar.blogspot.com
Are you over 18 and want to see adult content?
Family News and Product Buying Advice - Family Living Today
Are you over 18 and want to see adult content?
A complete backup of world4umovie24.blogspot.com
Are you over 18 and want to see adult content?
Kıbrıs Transfer | Taksi Fiyatları Ercan Havaalanı Girne
Are you over 18 and want to see adult content?
SPOLSHY - автозапчасти из Польши в Украину - б/у
Are you over 18 and want to see adult content?
Stock Market Trading Courses - Webinars - Training - and Mentoring
Are you over 18 and want to see adult content?
Better Diamonds, Lower Prices at Brilliance (Save up to 70%)
Are you over 18 and want to see adult content?
IcyBreeze Portable Air Conditioner & Cooler
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://mominoun.com
Are you over 18 and want to see adult content?
A complete backup of https://nticentral.org
Are you over 18 and want to see adult content?
A complete backup of https://newenglandboatshow.com
Are you over 18 and want to see adult content?
A complete backup of https://sunshineworks.com
Are you over 18 and want to see adult content?
A complete backup of https://professionalresearchpaperwriters.com
Are you over 18 and want to see adult content?
A complete backup of https://firstmet.club
Are you over 18 and want to see adult content?
A complete backup of https://ledpec.com
Are you over 18 and want to see adult content?
A complete backup of https://ourordinarylife.com
Are you over 18 and want to see adult content?
A complete backup of https://greatplacetowork.co.uk
Are you over 18 and want to see adult content?
A complete backup of https://hammerson.com
Are you over 18 and want to see adult content?
A complete backup of https://afterlunch.eu
Are you over 18 and want to see adult content?
A complete backup of https://bettronlive.io
Are you over 18 and want to see adult content?
Text
SYNGENEIC MODELS
1..2.66 | busdevcrownbio.com | www.crownbio.com Syngeneic Models Factsheet Figure 1: Basal Level of Immune Cells in Syngeneic Tumors A: T cell mean % of CD3 +, CD4 , CD8 , CD4 +/FOXP3 in TIL.B: Ratio of NOVEL EX VIVO 3D TUMOR GROWTH ASSAY FOR PDX DEVELOPED This publication details the development of a new 3D Tumor Growth Assay (3D-TGA), designed to grow tumor cells with minimal loss from low passage PDX models. The assay is aligned with the biochemical and biophysical properties of the patient tumor microenvironment, to mimic the paracrine signaling present in the microenvironment of solidtumors
IMMUNOCOMPETENT AML MODEL FOR PRECLINICAL EFFICACY TESTING An AML model with clinically relevant mutations for preclinical efficacy assessment of combinatory chemotherapies, targeted therapies, and immunotherapies. Model validation including immunoprofiling of PBMCs, showing high expression of PD-L1 and c-kit, and low TUMOR ORGANOID AND IMMUNE CELL CO-CULTURE SYSTEM Tumor Organoid and Immune Cell Co-Culture System Potentiates Immuno-Oncology Drug Development Patient-derived organoids (PDOs) are derived from adult epithelial stem PRECLINICAL ONCOLOGY CRO Crown Bioscience is an expert preclinical contract research organization providing oncology services and preclinical cancer models for drug development. CrownBio brings clarity to drug discovery worldwide, helping companies solve today's most pressing problems in immuno-oncology, oncology, cardiovascular, and metabolic diseases. ABOUT CROWN BIOSCIENCE CrownBio is a Cutting-Edge Translational Technology Company Making Precision Medicine a Reality. CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology and inflammation. Our premier Translational Platforms for cancer and inflammation help our OMNISCREEN - CELL BASED SCREENING SERVICE - CROWNBIO Well-Validated, Cost-Effective Screening. Take advantage of our quarterly revival of over 500 cancer cell lines, providing you significant cost savings.. Highlights of Omni Screen:. High throughput screening of at least 50 cell lines per run to maximize your savings; Positive drug control and cell line revival costs are included as part of Omni Screen; Unique subpanels built from CrownBio’s MUSCREEN - SYNGENEIC IN VIVO SCREEN - CROWNBIO High Throughput In Vivo Screens for Evaluating Immunotherapies. The Mu Screen platform is the only high throughput in vivo screen to evaluate immune modulating agents across preselected panels of well-characterized syngeneic and tumor homograft (Mu Prime™) models.. This screen provides a cost effective and time efficient way to fast-track in vivo preclinical immunotherapy development. MUBASE - ONCOLOGY DATABASES - CROWNBIO The vast array of murine cancer and immunotherapy models can make choosing the correct model for your research complicated and confusing. CrownBio has simplified the process by collating all our murine efficacy/PD and humanized models in one database ( MuBase), to allow side-by-side comparison and selection of appropriate models. AACR 2021 - CROWNBIO POSTERS Anti-human TNFR2 Antagonist can Induce T cell Proliferation and Restore T cell Balance to Promote Tumor Killing in TNFR2 HuGEMM Engrafted with MC38/OVA Tumor Cells. Session Category: Immunology. Session Title: Novel Animal Models.SYNGENEIC MODELS
1..2.66 | busdevcrownbio.com | www.crownbio.com Syngeneic Models Factsheet Figure 1: Basal Level of Immune Cells in Syngeneic Tumors A: T cell mean % of CD3 +, CD4 , CD8 , CD4 +/FOXP3 in TIL.B: Ratio of NOVEL EX VIVO 3D TUMOR GROWTH ASSAY FOR PDX DEVELOPED This publication details the development of a new 3D Tumor Growth Assay (3D-TGA), designed to grow tumor cells with minimal loss from low passage PDX models. The assay is aligned with the biochemical and biophysical properties of the patient tumor microenvironment, to mimic the paracrine signaling present in the microenvironment of solidtumors
IMMUNOCOMPETENT AML MODEL FOR PRECLINICAL EFFICACY TESTING An AML model with clinically relevant mutations for preclinical efficacy assessment of combinatory chemotherapies, targeted therapies, and immunotherapies. Model validation including immunoprofiling of PBMCs, showing high expression of PD-L1 and c-kit, and low TUMOR ORGANOID AND IMMUNE CELL CO-CULTURE SYSTEM Tumor Organoid and Immune Cell Co-Culture System Potentiates Immuno-Oncology Drug Development Patient-derived organoids (PDOs) are derived from adult epithelial stem ABOUT CROWN BIOSCIENCE CrownBio is a Cutting-Edge Translational Technology Company Making Precision Medicine a Reality. CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology and inflammation. Our premier Translational Platforms for cancer and inflammation help our CROWNBIO ONCOLOGY DATABASES Online database containing information for CrownBio’s immuno-oncology murine efficacy platforms: Syngeneic tumor models. Murine homograft models, MuPrime. GEMM. Humanized HuGEMM mouse models. MuBase provides the ability to search and browse the genomic, proteomic, and pharmacological profiles completed for these models tohelp identify the
WHAT WE DO | CROWNBIO Enabling Rapid, Scientifically-Sound Decision Making. Our portfolio of Translational Platforms for oncology and inflammation provide insight and understanding about a drug's efficacy, pharmacological profile and patient response profile, reducing failure in the clinic, and supporting the selection of the right patients for the right therapy.FLOW CYTOMETRY
Our standard flow cytometry panels have been validated in multiple oncology and inflammation in vivo models to provide basic to comprehensive analysis of lymphoid and myeloid cell populations. Models analyzed include syngeneics, tumor homografts ( MuPrime™ ), human target expressing ( HuGEMM™ / HuCELL™ ), humanized, GvHD,and peritonitis
3D IN VITRO HCI FOR IMMUNO-ONCOLOGY Version | usdecronioco | wwcronioco. Explore Scientific Data. Log into MuBase® to . review HuGEMM. TM. model data. hubase.crownbio.com. Contact Sales. US: +1 855 827 HUMANIZED MOUSE MODELS Human peripheral blood mononucleated cell (PBMC)-humanized mouse models provide a simple alternative to full stem cell reconstitution. Our MiXeno™ models are developed by combining human immune cells and conventional, cell line derived xenografts, with the resulting models showing reconstitution of T, B, and NK cell populations. PBMC CORPORATE HEADQUARTERS: ADVANCING IMMUNO-ONCOLOGY Corporate Headquarters: 16550 West Bernardo Drive Building 5, Suite 525 San Diego, CA 92127 Tel: 855.827.6968 Fax: 888.882.4881 www.crownbio.com Advancing Immuno-Oncology Therapies: What PATIENT-DERIVED ORGANOID AND IMMUNE CELL CO-CULTURES FOR HUB Organoids™: Unique Patented Technology for 3D In Vitro Tumor Modeling • HUB Organoids are the most clinically predictive 3D in vitro tumor models available.They serve as patient surrogates that recapitulate: – Diversity and heterogeneity of the patient population – Genomic, morphological, and pathophysiological characteristics of original epithelia/tumors MOUSE CLINICAL TRIALS, HUTRIAL™ Identify Responders, Partial, and Non-Responders Before You Enter the Clinic with Mouse Clinical Trials. With over 95% of new drugs failing Phase II and Phase III clinical trials due to a lack of efficacy and biomarker discovery, new translational technologies are required to make the oncology drug development process more efficient, to lower developmental costs, and to reduce attrition rates. CYST SWELLING ASSAY FOR ADPKD |usdecronioco | wwcronioco Functional Readouts Murine Cell Line Model of ADPKD • Murine Pkd1-/- collecting duct cells develop into cysts in 3D culture • cAMP-dependent cyst swelling is induced by forskolin or prostaglandin E2 • Test compounds are added and the effect on cyst swelling is determined • This robust model is suited to high-throughput screening PRECLINICAL ONCOLOGY CRO Crown Bioscience is an expert preclinical contract research organization providing oncology services and preclinical cancer models for drug development. CrownBio brings clarity to drug discovery worldwide, helping companies solve today's most pressing problems in immuno-oncology, oncology, cardiovascular, and metabolic diseases. OMNISCREEN - CELL BASED SCREENING SERVICE - CROWNBIO Well-Validated, Cost-Effective Screening. Take advantage of our quarterly revival of over 500 cancer cell lines, providing you significant cost savings.. Highlights of Omni Screen:. High throughput screening of at least 50 cell lines per run to maximize your savings; Positive drug control and cell line revival costs are included as part of Omni Screen; Unique subpanels built from CrownBio’s MUSCREEN - SYNGENEIC IN VIVO SCREEN - CROWNBIO High Throughput In Vivo Screens for Evaluating Immunotherapies. The Mu Screen platform is the only high throughput in vivo screen to evaluate immune modulating agents across preselected panels of well-characterized syngeneic and tumor homograft (Mu Prime™) models.. This screen provides a cost effective and time efficient way to fast-track in vivo preclinical immunotherapy development. MUBASE - ONCOLOGY DATABASES - CROWNBIO The vast array of murine cancer and immunotherapy models can make choosing the correct model for your research complicated and confusing. CrownBio has simplified the process by collating all our murine efficacy/PD and humanized models in one database ( MuBase), to allow side-by-side comparison and selection of appropriate models. MURINE HOMOGRAFT MODELS MUPRIME™, MOUSE TUMOR MODELS Mu Prime models provide an ideal platform to investigate your novel surrogate or cross-reactive immunotherapies with competent murine immunity, and the ability to synchronize tumor growth for pharmacology studies.. Mu Prime models are subcutaneous or orthotopic homografts from spontaneous, carcinogen-induced, or engineered GEMM tumors into immunocompetent syngeneic hosts.FLOW CYTOMETRY
Our standard flow cytometry panels have been validated in multiple oncology and inflammation in vivo models to provide basic to comprehensive analysis of lymphoid and myeloid cell populations. Models analyzed include syngeneics, tumor homografts ( MuPrime™ ), human target expressing ( HuGEMM™ / HuCELL™ ), humanized, GvHD,and peritonitis
SYNGENEIC MODELS
1..2.66 | busdevcrownbio.com | www.crownbio.com Syngeneic Models Factsheet Figure 1: Basal Level of Immune Cells in Syngeneic Tumors A: T cell mean % of CD3 +, CD4 , CD8 , CD4 +/FOXP3 in TIL.B: Ratio of IMMUNOCOMPETENT AML MODEL FOR PRECLINICAL EFFICACY TESTING An AML model with clinically relevant mutations for preclinical efficacy assessment of combinatory chemotherapies, targeted therapies, and immunotherapies. Model validation including immunoprofiling of PBMCs, showing high expression of PD-L1 and c-kit, and low TUMOR ORGANOID AND IMMUNE CELL CO-CULTURE SYSTEM Tumor Organoid and Immune Cell Co-Culture System Potentiates Immuno-Oncology Drug Development Patient-derived organoids (PDOs) are derived from adult epithelial stem FACILITATING DRUG DISCOVERY WITH 3D IN VITRO ONCOLOGY MODELS This post looks at advanced 3D in vitro models, including tumor spheroids and organoids.. Why Aren’t 2D In Vitro Models More Translatable?. Currently, a high proportion of drug discovery is performed using cell cultures. This increases the speed and efficiency of preclinical oncology research, but only so far as those results translate into the clinical environment. PRECLINICAL ONCOLOGY CRO Crown Bioscience is an expert preclinical contract research organization providing oncology services and preclinical cancer models for drug development. CrownBio brings clarity to drug discovery worldwide, helping companies solve today's most pressing problems in immuno-oncology, oncology, cardiovascular, and metabolic diseases. OMNISCREEN - CELL BASED SCREENING SERVICE - CROWNBIO Well-Validated, Cost-Effective Screening. Take advantage of our quarterly revival of over 500 cancer cell lines, providing you significant cost savings.. Highlights of Omni Screen:. High throughput screening of at least 50 cell lines per run to maximize your savings; Positive drug control and cell line revival costs are included as part of Omni Screen; Unique subpanels built from CrownBio’s MUSCREEN - SYNGENEIC IN VIVO SCREEN - CROWNBIO High Throughput In Vivo Screens for Evaluating Immunotherapies. The Mu Screen platform is the only high throughput in vivo screen to evaluate immune modulating agents across preselected panels of well-characterized syngeneic and tumor homograft (Mu Prime™) models.. This screen provides a cost effective and time efficient way to fast-track in vivo preclinical immunotherapy development. MUBASE - ONCOLOGY DATABASES - CROWNBIO The vast array of murine cancer and immunotherapy models can make choosing the correct model for your research complicated and confusing. CrownBio has simplified the process by collating all our murine efficacy/PD and humanized models in one database ( MuBase), to allow side-by-side comparison and selection of appropriate models. MURINE HOMOGRAFT MODELS MUPRIME™, MOUSE TUMOR MODELS Mu Prime models provide an ideal platform to investigate your novel surrogate or cross-reactive immunotherapies with competent murine immunity, and the ability to synchronize tumor growth for pharmacology studies.. Mu Prime models are subcutaneous or orthotopic homografts from spontaneous, carcinogen-induced, or engineered GEMM tumors into immunocompetent syngeneic hosts.FLOW CYTOMETRY
Our standard flow cytometry panels have been validated in multiple oncology and inflammation in vivo models to provide basic to comprehensive analysis of lymphoid and myeloid cell populations. Models analyzed include syngeneics, tumor homografts ( MuPrime™ ), human target expressing ( HuGEMM™ / HuCELL™ ), humanized, GvHD,and peritonitis
SYNGENEIC MODELS
1..2.66 | busdevcrownbio.com | www.crownbio.com Syngeneic Models Factsheet Figure 1: Basal Level of Immune Cells in Syngeneic Tumors A: T cell mean % of CD3 +, CD4 , CD8 , CD4 +/FOXP3 in TIL.B: Ratio of IMMUNOCOMPETENT AML MODEL FOR PRECLINICAL EFFICACY TESTING An AML model with clinically relevant mutations for preclinical efficacy assessment of combinatory chemotherapies, targeted therapies, and immunotherapies. Model validation including immunoprofiling of PBMCs, showing high expression of PD-L1 and c-kit, and low TUMOR ORGANOID AND IMMUNE CELL CO-CULTURE SYSTEM Tumor Organoid and Immune Cell Co-Culture System Potentiates Immuno-Oncology Drug Development Patient-derived organoids (PDOs) are derived from adult epithelial stem FACILITATING DRUG DISCOVERY WITH 3D IN VITRO ONCOLOGY MODELS This post looks at advanced 3D in vitro models, including tumor spheroids and organoids.. Why Aren’t 2D In Vitro Models More Translatable?. Currently, a high proportion of drug discovery is performed using cell cultures. This increases the speed and efficiency of preclinical oncology research, but only so far as those results translate into the clinical environment. HIGH CONTENT IMAGING SERVICES Explore the Power of High Content Imaging. High content imaging and analysis of 3D in vitro models, such as organoids and spheroid cultures, provide invaluable information that gives researchers greater insights into complex disease pathophysiology for more effective assessment of novel compounds and new therapeutic modalities.. Utilizing OcellO technology, CrownBio offers a suite ofpowerful
FLOW CYTOMETRY
Our standard flow cytometry panels have been validated in multiple oncology and inflammation in vivo models to provide basic to comprehensive analysis of lymphoid and myeloid cell populations. Models analyzed include syngeneics, tumor homografts ( MuPrime™ ), human target expressing ( HuGEMM™ / HuCELL™ ), humanized, GvHD,and peritonitis
XENOBASE | ONCOLOGY DATABASE | CROWNBIO Find Your Cell Lines and Models of Interest in One Easy Search. Using appropriate cell lines and Cell Line Derived Xenograft models with genetic features of interest can enhance your early stage in vitro and in vivo drug discovery programs. CrownBio has made searching for cell lines and xenografts easy using XenoBase, our collated onlinedatabase.
ORGANOIDS FOR ONCOLOGY DRUG DEVELOPMENT Progress Oncology Drug Development with Organoids Developed using HUB Protocols. Incorporate the most translatable 3D in vitro models available into your oncology drug development programs. We exclusively provide preclinical oncology drug development and validation services using unique organoid models developed using IP-protected Hubrecht Organoid Technology (HUB) protocols, as well as HUB MOUSE CLINICAL TRIALS, HUTRIAL™ Identify Responders, Partial, and Non-Responders Before You Enter the Clinic with Mouse Clinical Trials. With over 95% of new drugs failing Phase II and Phase III clinical trials due to a lack of efficacy and biomarker discovery, new translational technologies are required to make the oncology drug development process more efficient, to lower developmental costs, and to reduce attrition rates. CORPORATE HEADQUARTERS: ADVANCING IMMUNO-ONCOLOGY Corporate Headquarters: 16550 West Bernardo Drive Building 5, Suite 525 San Diego, CA 92127 Tel: 855.827.6968 Fax: 888.882.4881 www.crownbio.com Advancing Immuno-Oncology Therapies: What HUGEMM | IN VIVO IMMUNO-ONCOLOGY | CROWNBIO Robust Humanized Target Model Platform for Immunotherapy Evaluation. The preclinical evaluation of immunotherapies has been hindered by a lack of in vivo models for testing human-specific therapeutics.Surrogate anti-mouse checkpoint inhibitors were initially evaluated in syngeneics, however these models cannot be used for testing human biological therapeutics due to species specificityissues.
NEW METHOD FOR DETECTING AND MONITORING CAR-T CELLS IN A new method for detecting and monitoring CAR-T cells in the clinical setting, which could become a useful diagnostic to provide guidance on the treatment and prognosis of patients. Preliminary data showing the high sensitivity of our method (3 orders of magnitude above flow cytometry) and a good linear range of quantification. How the method SITC20 POSTER 647: HUMANIZED CD137 KNOCK-IN MOUSE MODEL TO Evaluation of Efficacy and Toxicity of CD137 Immunotherapy with Urelumab-mIgG1 Chimeric Antibody in CD137 Hu GEMM™. Hongjuan Zhang, Daniel X. He, Xinhe Feng, Mingkun Zhang *, Annie X.An, Cunxiang Ju *, Chen Jiang, Xiaolong Tu, Henry Q. X. Li, Davy X. Ouyang * GemPharmatech CD137 is an attractive immuno-oncology therapeutic target with multiple agonistic antibodies already in clinical testing. IDENTIFICATION OF APILIMOD AS A FIRST-IN-CLASS PIKFYVE the cytotoxic effects of apilimod. Collectively, these findings provide a promising new approach for treating multiple subtypes of B-NHL as a single agent, or in combination with existing therapies. PRECLINICAL ONCOLOGY CRO Crown Bioscience is an expert preclinical contract research organization providing oncology services and preclinical cancer models for drug development. CrownBio brings clarity to drug discovery worldwide, helping companies solve today's most pressing problems in immuno-oncology, oncology, cardiovascular, and metabolic diseases. MUSCREEN - SYNGENEIC IN VIVO SCREEN - CROWNBIO High Throughput In Vivo Screens for Evaluating Immunotherapies. The Mu Screen platform is the only high throughput in vivo screen to evaluate immune modulating agents across preselected panels of well-characterized syngeneic and tumor homograft (Mu Prime™) models.. This screen provides a cost effective and time efficient way to fast-track in vivo preclinical immunotherapy development. OMNISCREEN - CELL BASED SCREENING SERVICE - CROWNBIO Well-Validated, Cost-Effective Screening. Take advantage of our quarterly revival of over 500 cancer cell lines, providing you significant cost savings.. Highlights of Omni Screen:. High throughput screening of at least 50 cell lines per run to maximize your savings; Positive drug control and cell line revival costs are included as part of Omni Screen; Unique subpanels built from CrownBio’s MUBASE - ONCOLOGY DATABASES - CROWNBIO The vast array of murine cancer and immunotherapy models can make choosing the correct model for your research complicated and confusing. CrownBio has simplified the process by collating all our murine efficacy/PD and humanized models in one database ( MuBase), to allow side-by-side comparison and selection of appropriate models.FLOW CYTOMETRY
Our standard flow cytometry panels have been validated in multiple oncology and inflammation in vivo models to provide basic to comprehensive analysis of lymphoid and myeloid cell populations. Models analyzed include syngeneics, tumor homografts ( MuPrime™ ), human target expressing ( HuGEMM™ / HuCELL™ ), humanized, GvHD,and peritonitis
CORPORATE HEADQUARTERS: ADVANCING IMMUNO-ONCOLOGY Corporate Headquarters: 16550 West Bernardo Drive Building 5, Suite 525 San Diego, CA 92127 Tel: 855.827.6968 Fax: 888.882.4881 www.crownbio.com Advancing Immuno-Oncology Therapies: WhatSYNGENEIC MODELS
1..2.66 | busdevcrownbio.com | www.crownbio.com Syngeneic Models Factsheet Figure 1: Basal Level of Immune Cells in Syngeneic Tumors A: T cell mean % of CD3 +, CD4 , CD8 , CD4 +/FOXP3 in TIL.B: Ratio of PATIENT-DERIVED ORGANOID AND IMMUNE CELL CO-CULTURES FOR HUB Organoids™: Unique Patented Technology for 3D In Vitro Tumor Modeling • HUB Organoids are the most clinically predictive 3D in vitro tumor models available.They serve as patient surrogates that recapitulate: – Diversity and heterogeneity of the patient population – Genomic, morphological, and pathophysiological characteristics of original epithelia/tumors NOVEL EX VIVO 3D TUMOR GROWTH ASSAY FOR PDX DEVELOPED This publication details the development of a new 3D Tumor Growth Assay (3D-TGA), designed to grow tumor cells with minimal loss from low passage PDX models. The assay is aligned with the biochemical and biophysical properties of the patient tumor microenvironment, to mimic the paracrine signaling present in the microenvironment of solidtumors
TUMOR ORGANOID AND IMMUNE CELL CO-CULTURE SYSTEM Tumor Organoid and Immune Cell Co-Culture System Potentiates Immuno-Oncology Drug Development Patient-derived organoids (PDOs) are derived from adult epithelial stem PRECLINICAL ONCOLOGY CRO Crown Bioscience is an expert preclinical contract research organization providing oncology services and preclinical cancer models for drug development. CrownBio brings clarity to drug discovery worldwide, helping companies solve today's most pressing problems in immuno-oncology, oncology, cardiovascular, and metabolic diseases. MUSCREEN - SYNGENEIC IN VIVO SCREEN - CROWNBIO High Throughput In Vivo Screens for Evaluating Immunotherapies. The Mu Screen platform is the only high throughput in vivo screen to evaluate immune modulating agents across preselected panels of well-characterized syngeneic and tumor homograft (Mu Prime™) models.. This screen provides a cost effective and time efficient way to fast-track in vivo preclinical immunotherapy development. OMNISCREEN - CELL BASED SCREENING SERVICE - CROWNBIO Well-Validated, Cost-Effective Screening. Take advantage of our quarterly revival of over 500 cancer cell lines, providing you significant cost savings.. Highlights of Omni Screen:. High throughput screening of at least 50 cell lines per run to maximize your savings; Positive drug control and cell line revival costs are included as part of Omni Screen; Unique subpanels built from CrownBio’s MUBASE - ONCOLOGY DATABASES - CROWNBIO The vast array of murine cancer and immunotherapy models can make choosing the correct model for your research complicated and confusing. CrownBio has simplified the process by collating all our murine efficacy/PD and humanized models in one database ( MuBase), to allow side-by-side comparison and selection of appropriate models.FLOW CYTOMETRY
Our standard flow cytometry panels have been validated in multiple oncology and inflammation in vivo models to provide basic to comprehensive analysis of lymphoid and myeloid cell populations. Models analyzed include syngeneics, tumor homografts ( MuPrime™ ), human target expressing ( HuGEMM™ / HuCELL™ ), humanized, GvHD,and peritonitis
CORPORATE HEADQUARTERS: ADVANCING IMMUNO-ONCOLOGY Corporate Headquarters: 16550 West Bernardo Drive Building 5, Suite 525 San Diego, CA 92127 Tel: 855.827.6968 Fax: 888.882.4881 www.crownbio.com Advancing Immuno-Oncology Therapies: WhatSYNGENEIC MODELS
1..2.66 | busdevcrownbio.com | www.crownbio.com Syngeneic Models Factsheet Figure 1: Basal Level of Immune Cells in Syngeneic Tumors A: T cell mean % of CD3 +, CD4 , CD8 , CD4 +/FOXP3 in TIL.B: Ratio of PATIENT-DERIVED ORGANOID AND IMMUNE CELL CO-CULTURES FOR HUB Organoids™: Unique Patented Technology for 3D In Vitro Tumor Modeling • HUB Organoids are the most clinically predictive 3D in vitro tumor models available.They serve as patient surrogates that recapitulate: – Diversity and heterogeneity of the patient population – Genomic, morphological, and pathophysiological characteristics of original epithelia/tumors NOVEL EX VIVO 3D TUMOR GROWTH ASSAY FOR PDX DEVELOPED This publication details the development of a new 3D Tumor Growth Assay (3D-TGA), designed to grow tumor cells with minimal loss from low passage PDX models. The assay is aligned with the biochemical and biophysical properties of the patient tumor microenvironment, to mimic the paracrine signaling present in the microenvironment of solidtumors
TUMOR ORGANOID AND IMMUNE CELL CO-CULTURE SYSTEM Tumor Organoid and Immune Cell Co-Culture System Potentiates Immuno-Oncology Drug Development Patient-derived organoids (PDOs) are derived from adult epithelial stem HIGH CONTENT IMAGING SERVICES Explore the Power of High Content Imaging. High content imaging and analysis of 3D in vitro models, such as organoids and spheroid cultures, provide invaluable information that gives researchers greater insights into complex disease pathophysiology for more effective assessment of novel compounds and new therapeutic modalities.. Utilizing OcellO technology, CrownBio offers a suite ofpowerful
ABOUT CROWN BIOSCIENCE CrownBio is a Cutting-Edge Translational Technology Company Making Precision Medicine a Reality. CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology and inflammation. Our premier Translational Platforms for cancer and inflammation help our OMNISCREEN - CELL BASED SCREENING SERVICE - CROWNBIO Well-Validated, Cost-Effective Screening. Take advantage of our quarterly revival of over 500 cancer cell lines, providing you significant cost savings.. Highlights of Omni Screen:. High throughput screening of at least 50 cell lines per run to maximize your savings; Positive drug control and cell line revival costs are included as part of Omni Screen; Unique subpanels built from CrownBio’s CROWNVIVO™ ISOTYPE CONTROLS Our isotype control antibodies are still made in the same facility under the same chemically defined animal free conditions. The same quality reagents you’ve come to expect from CrownBio are now available exclusively through MBL International. Available in high concentrations in bulk quantities Low Endotoxin (≤ 1 EU/mg) Vialed in PBS only – No preservativesCAREERS | CROWNBIO
The mission of CrownBio is to address the unmet needs in life science by creating and supplying innovative translational technologies and platforms. Our products and services have been profoundly expediting research for in vitro, in vivo, translational oncology, target validation, preclinical proof of concept, assistive clinical strategydesign
FLOW CYTOMETRY
Our standard flow cytometry panels have been validated in multiple oncology and inflammation in vivo models to provide basic to comprehensive analysis of lymphoid and myeloid cell populations. Models analyzed include syngeneics, tumor homografts ( MuPrime™ ), human target expressing ( HuGEMM™ / HuCELL™ ), humanized, GvHD,and peritonitis
XENOBASE | ONCOLOGY DATABASE | CROWNBIO Find Your Cell Lines and Models of Interest in One Easy Search. Using appropriate cell lines and Cell Line Derived Xenograft models with genetic features of interest can enhance your early stage in vitro and in vivo drug discovery programs. CrownBio has made searching for cell lines and xenografts easy using XenoBase, our collated onlinedatabase.
QUICKFACT: GENOMIC SERVICES Publication: Decreasing Giloma Secondary Mutations to Delay Tumour Recurrence. Publication: Barcode Deep NGS-Based Profiling of Oncology Samples. Publication: The Desgin, Analysis and Application of Mouse Clinical Trials in Oncology Drug Development. Quickfact: Mouse I/O RNA-Seq Panel. Quickfact: Genomics Services. MOUSE CLINICAL TRIALS, HUTRIAL™ Identify Responders, Partial, and Non-Responders Before You Enter the Clinic with Mouse Clinical Trials. With over 95% of new drugs failing Phase II and Phase III clinical trials due to a lack of efficacy and biomarker discovery, new translational technologies are required to make the oncology drug development process more efficient, to lower developmental costs, and to reduce attrition rates. HEMATOPOIETIC STEM CELL (HSC)-PDX Evaluate your Immunotherapeutics with Humanized, Highly Predictive Hematopoietic Stem Cell PDX models. A lack of experimental models featuring a fully functional human immune system is a major obstacle in the evaluation of novel human immunotherapeutics. PRECLINICAL ONCOLOGY CRO Crown Bioscience is an expert preclinical contract research organization providing oncology services and preclinical cancer models for drug development. CrownBio brings clarity to drug discovery worldwide, helping companies solve today's most pressing problems in immuno-oncology, oncology, cardiovascular, and metabolic diseases. MUSCREEN - SYNGENEIC IN VIVO SCREEN - CROWNBIO High Throughput In Vivo Screens for Evaluating Immunotherapies. The Mu Screen platform is the only high throughput in vivo screen to evaluate immune modulating agents across preselected panels of well-characterized syngeneic and tumor homograft (Mu Prime™) models.. This screen provides a cost effective and time efficient way to fast-track in vivo preclinical immunotherapy development. OMNISCREEN - CELL BASED SCREENING SERVICE - CROWNBIO Well-Validated, Cost-Effective Screening. Take advantage of our quarterly revival of over 500 cancer cell lines, providing you significant cost savings.. Highlights of Omni Screen:. High throughput screening of at least 50 cell lines per run to maximize your savings; Positive drug control and cell line revival costs are included as part of Omni Screen; Unique subpanels built from CrownBio’s MUBASE - ONCOLOGY DATABASES - CROWNBIO The vast array of murine cancer and immunotherapy models can make choosing the correct model for your research complicated and confusing. CrownBio has simplified the process by collating all our murine efficacy/PD and humanized models in one database ( MuBase), to allow side-by-side comparison and selection of appropriate models. CROWNVIVO™ ISOTYPE CONTROLS Our isotype control antibodies are still made in the same facility under the same chemically defined animal free conditions. The same quality reagents you’ve come to expect from CrownBio are now available exclusively through MBL International. Available in high concentrations in bulk quantities Low Endotoxin (≤ 1 EU/mg) Vialed in PBS only – No preservatives CORPORATE HEADQUARTERS: ADVANCING IMMUNO-ONCOLOGY Corporate Headquarters: 16550 West Bernardo Drive Building 5, Suite 525 San Diego, CA 92127 Tel: 855.827.6968 Fax: 888.882.4881 www.crownbio.com Advancing Immuno-Oncology Therapies: WhatSYNGENEIC MODELS
1..2.66 | busdevcrownbio.com | www.crownbio.com Syngeneic Models Factsheet Figure 1: Basal Level of Immune Cells in Syngeneic Tumors A: T cell mean % of CD3 +, CD4 , CD8 , CD4 +/FOXP3 in TIL.B: Ratio of PATIENT-DERIVED ORGANOID AND IMMUNE CELL CO-CULTURES FOR HUB Organoids™: Unique Patented Technology for 3D In Vitro Tumor Modeling • HUB Organoids are the most clinically predictive 3D in vitro tumor models available.They serve as patient surrogates that recapitulate: – Diversity and heterogeneity of the patient population – Genomic, morphological, and pathophysiological characteristics of original epithelia/tumors NOVEL EX VIVO 3D TUMOR GROWTH ASSAY FOR PDX DEVELOPED This publication details the development of a new 3D Tumor Growth Assay (3D-TGA), designed to grow tumor cells with minimal loss from low passage PDX models. The assay is aligned with the biochemical and biophysical properties of the patient tumor microenvironment, to mimic the paracrine signaling present in the microenvironment of solidtumors
TUMOR ORGANOID AND IMMUNE CELL CO-CULTURE SYSTEM Tumor Organoid and Immune Cell Co-Culture System Potentiates Immuno-Oncology Drug Development Patient-derived organoids (PDOs) are derived from adult epithelial stem PRECLINICAL ONCOLOGY CRO Crown Bioscience is an expert preclinical contract research organization providing oncology services and preclinical cancer models for drug development. CrownBio brings clarity to drug discovery worldwide, helping companies solve today's most pressing problems in immuno-oncology, oncology, cardiovascular, and metabolic diseases. MUSCREEN - SYNGENEIC IN VIVO SCREEN - CROWNBIO High Throughput In Vivo Screens for Evaluating Immunotherapies. The Mu Screen platform is the only high throughput in vivo screen to evaluate immune modulating agents across preselected panels of well-characterized syngeneic and tumor homograft (Mu Prime™) models.. This screen provides a cost effective and time efficient way to fast-track in vivo preclinical immunotherapy development. OMNISCREEN - CELL BASED SCREENING SERVICE - CROWNBIO Well-Validated, Cost-Effective Screening. Take advantage of our quarterly revival of over 500 cancer cell lines, providing you significant cost savings.. Highlights of Omni Screen:. High throughput screening of at least 50 cell lines per run to maximize your savings; Positive drug control and cell line revival costs are included as part of Omni Screen; Unique subpanels built from CrownBio’s MUBASE - ONCOLOGY DATABASES - CROWNBIO The vast array of murine cancer and immunotherapy models can make choosing the correct model for your research complicated and confusing. CrownBio has simplified the process by collating all our murine efficacy/PD and humanized models in one database ( MuBase), to allow side-by-side comparison and selection of appropriate models. CROWNVIVO™ ISOTYPE CONTROLS Our isotype control antibodies are still made in the same facility under the same chemically defined animal free conditions. The same quality reagents you’ve come to expect from CrownBio are now available exclusively through MBL International. Available in high concentrations in bulk quantities Low Endotoxin (≤ 1 EU/mg) Vialed in PBS only – No preservatives CORPORATE HEADQUARTERS: ADVANCING IMMUNO-ONCOLOGY Corporate Headquarters: 16550 West Bernardo Drive Building 5, Suite 525 San Diego, CA 92127 Tel: 855.827.6968 Fax: 888.882.4881 www.crownbio.com Advancing Immuno-Oncology Therapies: WhatSYNGENEIC MODELS
1..2.66 | busdevcrownbio.com | www.crownbio.com Syngeneic Models Key Facts CrownBio provides a well characterized Syngeneic Model Panel: • Over 30 models covering 15 cancer types, with further models undergoing validation. PATIENT-DERIVED ORGANOID AND IMMUNE CELL CO-CULTURES FOR HUB Organoids™: Unique Patented Technology for 3D In Vitro Tumor Modeling • HUB Organoids are the most clinically predictive 3D in vitro tumor models available.They serve as patient surrogates that recapitulate: – Diversity and heterogeneity of the patient population – Genomic, morphological, and pathophysiological characteristics of original epithelia/tumors NOVEL EX VIVO 3D TUMOR GROWTH ASSAY FOR PDX DEVELOPED This publication details the development of a new 3D Tumor Growth Assay (3D-TGA), designed to grow tumor cells with minimal loss from low passage PDX models. The assay is aligned with the biochemical and biophysical properties of the patient tumor microenvironment, to mimic the paracrine signaling present in the microenvironment of solidtumors
TUMOR ORGANOID AND IMMUNE CELL CO-CULTURE SYSTEM Tumor Organoid and Immune Cell Co-Culture System Potentiates Immuno-Oncology Drug Development Patient-derived organoids (PDOs) are derived from adult epithelial stem HIGH CONTENT IMAGING SERVICES Explore the Power of High Content Imaging. High content imaging and analysis of 3D in vitro models, such as organoids and spheroid cultures, provide invaluable information that gives researchers greater insights into complex disease pathophysiology for more effective assessment of novel compounds and new therapeutic modalities.. Utilizing OcellO technology, CrownBio offers a suite ofpowerful
OMNISCREEN - CELL BASED SCREENING SERVICE - CROWNBIO Well-Validated, Cost-Effective Screening. Take advantage of our quarterly revival of over 500 cancer cell lines, providing you significant cost savings.. Highlights of Omni Screen:. High throughput screening of at least 50 cell lines per run to maximize your savings; Positive drug control and cell line revival costs are included as part of Omni Screen; Unique subpanels built from CrownBio’s CROWNVIVO™ ISOTYPE CONTROLS Our isotype control antibodies are still made in the same facility under the same chemically defined animal free conditions. The same quality reagents you’ve come to expect from CrownBio are now available exclusively through MBL International. Available in high concentrations in bulk quantities Low Endotoxin (≤ 1 EU/mg) Vialed in PBS only – No preservatives CONTACT US | CROWNBIO Crown Bioscience San Diego 16550 West Bernardo Drive Building 5, Suite 525 San Diego, CA 92127 USA Tel: +1 858 622 2900CAREERS | CROWNBIO
The mission of CrownBio is to address the unmet needs in life science by creating and supplying innovative translational technologies and platforms. Our products and services have been profoundly expediting research for in vitro, in vivo, translational oncology, target validation, preclinical proof of concept, assistive clinical strategydesign
XENOBASE | ONCOLOGY DATABASE | CROWNBIO Find Your Cell Lines and Models of Interest in One Easy Search. Using appropriate cell lines and Cell Line Derived Xenograft models with genetic features of interest can enhance your early stage in vitro and in vivo drug discovery programs. CrownBio has made searching for cell lines and xenografts easy using XenoBase, our collated onlinedatabase.
MOUSE CLINICAL TRIALS, HUTRIAL™ Identify Responders, Partial, and Non-Responders Before You Enter the Clinic with Mouse Clinical Trials. With over 95% of new drugs failing Phase II and Phase III clinical trials due to a lack of efficacy and biomarker discovery, new translational technologies are required to make the oncology drug development process more efficient, to lower developmental costs, and to reduce attrition rates. PATIENT-DERIVED XENOGRAFT Patient-derived xenografts - PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of howyour
HEMATOPOIETIC STEM CELL (HSC)-PDX Evaluate your Immunotherapeutics with Humanized, Highly Predictive Hematopoietic Stem Cell PDX models. A lack of experimental models featuring a fully functional human immune system is a major obstacle in the evaluation of novel human immunotherapeutics. KEY APPLICATIONS OF SYNGENEIC TUMOR MODELS TO MAXIMIZE I/O 3 +1.855.827.6968 | busdevcrownbio.com | www.crownbio.com Using Syngeneic Models for POC Studies For POC studies, syngeneic models offer a rapid and cost-effective approach that has potential for high throughput, alongside historic data for comparison with novel PRECLINICAL ONCOLOGY CRO Crown Bioscience is an expert preclinical contract research organization providing oncology services and preclinical cancer models for drug development. CrownBio brings clarity to drug discovery worldwide, helping companies solve today's most pressing problems in immuno-oncology, oncology, cardiovascular, and metabolic diseases. OMNISCREEN - CELL BASED SCREENING SERVICE - CROWNBIO Well-Validated, Cost-Effective Screening. Take advantage of our quarterly revival of over 500 cancer cell lines, providing you significant cost savings.. Highlights of Omni Screen:. High throughput screening of at least 50 cell lines per run to maximize your savings; Positive drug control and cell line revival costs are included as part of Omni Screen; Unique subpanels built from CrownBio’s MUSCREEN - SYNGENEIC IN VIVO SCREEN - CROWNBIO High Throughput In Vivo Screens for Evaluating Immunotherapies. The Mu Screen platform is the only high throughput in vivo screen to evaluate immune modulating agents across preselected panels of well-characterized syngeneic and tumor homograft (Mu Prime™) models.. This screen provides a cost effective and time efficient way to fast-track in vivo preclinical immunotherapy development. MUBASE - ONCOLOGY DATABASES - CROWNBIO The vast array of murine cancer and immunotherapy models can make choosing the correct model for your research complicated and confusing. CrownBio has simplified the process by collating all our murine efficacy/PD and humanized models in one database ( MuBase), to allow side-by-side comparison and selection of appropriate models. INFLAMMATION & IMMUNOLOGY In Vivo. Inflammatory and Autoimmune Disease Models. Our catalogue of inflammation models recapitulates key clinical and pathological features of human disease, forming an integrated platform for preclinical drug development. Model diverse autoimmune and inflammatory disease mechanisms in vivo. Determine agent efficacy and response to treatment.SYNGENEIC MODELS
1..2.66 | busdevcrownbio.com | www.crownbio.com Syngeneic Models Key Facts CrownBio provides a well characterized Syngeneic Model Panel: • Over 30 models covering 15 cancer types, with further models undergoing validation.MS-NASH MODEL
The MS-NASH (formerly called FATZO) mouse model was created by inducing NAFLD/NASH through administration of a “Western diet” plus fructose. On diet, the model develops steatosis, hepatocyte ballooning, inflammation, and fibrosis over time. Progression and exacerbated NASH pathology is accelerated with administration of CCl4.
NOVEL EX VIVO 3D TUMOR GROWTH ASSAY FOR PDX DEVELOPED This publication details the development of a new 3D Tumor Growth Assay (3D-TGA), designed to grow tumor cells with minimal loss from low passage PDX models. The assay is aligned with the biochemical and biophysical properties of the patient tumor microenvironment, to mimic the paracrine signaling present in the microenvironment of solidtumors
TARGETING THE CD47/SIRPⱭ AXIS IN CANCER IMMUNOTHERAPY The CD47/SIRPɑ Axis in Immuno-Oncology. Since formation of the CD47/SIRPα axis is important for tumor progression, blockage of this axis may be an effective mode of cancer therapy. Molecules developed to block this axis typically fall into one of three categories: Molecules that target CD47 alone. Molecules that target SIRPα alone. COMPARISON GUIDE: HUNOG® & HUNSG™ HUMANIZED MODELS The first mouse used to transplant human cells was the athymic nude mouse, discovered in the 1960s. Nude mice have a mutation in the Foxn1 gene, which causes a deteriorated or absent thymus, and results in a greatly reduced number of T cells.. While human cells can be engrafted, and a number of human cancer cell lines have been established in nude mice, the few remaining T cells and residual PRECLINICAL ONCOLOGY CRO Crown Bioscience is an expert preclinical contract research organization providing oncology services and preclinical cancer models for drug development. CrownBio brings clarity to drug discovery worldwide, helping companies solve today's most pressing problems in immuno-oncology, oncology, cardiovascular, and metabolic diseases. OMNISCREEN - CELL BASED SCREENING SERVICE - CROWNBIO Well-Validated, Cost-Effective Screening. Take advantage of our quarterly revival of over 500 cancer cell lines, providing you significant cost savings.. Highlights of Omni Screen:. High throughput screening of at least 50 cell lines per run to maximize your savings; Positive drug control and cell line revival costs are included as part of Omni Screen; Unique subpanels built from CrownBio’s MUSCREEN - SYNGENEIC IN VIVO SCREEN - CROWNBIO High Throughput In Vivo Screens for Evaluating Immunotherapies. The Mu Screen platform is the only high throughput in vivo screen to evaluate immune modulating agents across preselected panels of well-characterized syngeneic and tumor homograft (Mu Prime™) models.. This screen provides a cost effective and time efficient way to fast-track in vivo preclinical immunotherapy development. MUBASE - ONCOLOGY DATABASES - CROWNBIO The vast array of murine cancer and immunotherapy models can make choosing the correct model for your research complicated and confusing. CrownBio has simplified the process by collating all our murine efficacy/PD and humanized models in one database ( MuBase), to allow side-by-side comparison and selection of appropriate models. INFLAMMATION & IMMUNOLOGY In Vivo. Inflammatory and Autoimmune Disease Models. Our catalogue of inflammation models recapitulates key clinical and pathological features of human disease, forming an integrated platform for preclinical drug development. Model diverse autoimmune and inflammatory disease mechanisms in vivo. Determine agent efficacy and response to treatment.SYNGENEIC MODELS
1..2.66 | busdevcrownbio.com | www.crownbio.com Syngeneic Models Key Facts CrownBio provides a well characterized Syngeneic Model Panel: • Over 30 models covering 15 cancer types, with further models undergoing validation.MS-NASH MODEL
The MS-NASH (formerly called FATZO) mouse model was created by inducing NAFLD/NASH through administration of a “Western diet” plus fructose. On diet, the model develops steatosis, hepatocyte ballooning, inflammation, and fibrosis over time. Progression and exacerbated NASH pathology is accelerated with administration of CCl4.
NOVEL EX VIVO 3D TUMOR GROWTH ASSAY FOR PDX DEVELOPED This publication details the development of a new 3D Tumor Growth Assay (3D-TGA), designed to grow tumor cells with minimal loss from low passage PDX models. The assay is aligned with the biochemical and biophysical properties of the patient tumor microenvironment, to mimic the paracrine signaling present in the microenvironment of solidtumors
TARGETING THE CD47/SIRPⱭ AXIS IN CANCER IMMUNOTHERAPY The CD47/SIRPɑ Axis in Immuno-Oncology. Since formation of the CD47/SIRPα axis is important for tumor progression, blockage of this axis may be an effective mode of cancer therapy. Molecules developed to block this axis typically fall into one of three categories: Molecules that target CD47 alone. Molecules that target SIRPα alone. COMPARISON GUIDE: HUNOG® & HUNSG™ HUMANIZED MODELS The first mouse used to transplant human cells was the athymic nude mouse, discovered in the 1960s. Nude mice have a mutation in the Foxn1 gene, which causes a deteriorated or absent thymus, and results in a greatly reduced number of T cells.. While human cells can be engrafted, and a number of human cancer cell lines have been established in nude mice, the few remaining T cells and residual CROWNBIO ONCOLOGY DATABASES Online database containing information for CrownBio’s immuno-oncology murine efficacy platforms: Syngeneic tumor models. Murine homograft models, MuPrime. GEMM. Humanized HuGEMM mouse models. MuBase provides the ability to search and browse the genomic, proteomic, and pharmacological profiles completed for these models tohelp identify the
CROWNVIVO™ ISOTYPE CONTROLS Our isotype control antibodies are still made in the same facility under the same chemically defined animal free conditions. The same quality reagents you’ve come to expect from CrownBio are now available exclusively through MBL International. Available in high concentrations in bulk quantities Low Endotoxin (≤ 1 EU/mg) Vialed in PBS only – No preservatives INFLAMMATION & IMMUNOLOGY In Vivo. Inflammatory and Autoimmune Disease Models. Our catalogue of inflammation models recapitulates key clinical and pathological features of human disease, forming an integrated platform for preclinical drug development. Model diverse autoimmune and inflammatory disease mechanisms in vivo. Determine agent efficacy and response to treatment. XENOBASE | ONCOLOGY DATABASE | CROWNBIO Find Your Cell Lines and Models of Interest in One Easy Search. Using appropriate cell lines and Cell Line Derived Xenograft models with genetic features of interest can enhance your early stage in vitro and in vivo drug discovery programs. CrownBio has made searching for cell lines and xenografts easy using XenoBase, our collated onlinedatabase.
HUMANIZED MOUSE MODELS Human peripheral blood mononucleated cell (PBMC)-humanized mouse models provide a simple alternative to full stem cell reconstitution. Our MiXeno™ models are developed by combining human immune cells and conventional, cell line derived xenografts, with the resulting models showing reconstitution of T, B, and NK cell populations. PBMCCROWNBIO - LOGIN
Authorized Use. You are hereby granted a limited, non-exclusive, non-sublicensable license to use the Data contained in the Databases solely for model selection to be later conducted in a study project carried out by CrownBio and for no other purposes (“Purpose”). SYMPOSIUM ONCOLOGY DRUG DISCOVERY: NOVEL PERSPECTIVES AND Join CrownBio at our SYMPOSIUM Oncology Drug Discovery: Novel Perspectives and the Immuno-Oncology Generation. Reserve your seat online today or call 1.855.827.6968 CD137: AN IMPORTANT TARGET IN T CELL CO-STIMULATION Following on from OX40, our TNF superfamily posts continue with CD137, another important target in T cell co-stimulation.. CD137 Stimulates the Immune System Against Cancer Cells. In contrast to the mode of action of checkpoint inhibitors (which is to block a ligand/receptor interaction) there is another class of immunomodulatory targets in the immuno-oncology world – the co ICOS: IMMUNOSTIMULATORY OR IMMUNOSUPPRESSIVE TARGET? A third member of the CD28/CTLA-4 family is the inducible co-stimulator (ICOS). ICOS is a homodimeric protein which is expressed on activated T cells, and only at low levels on resting, naïve T cells. ICOS binds specifically to its ligand (ICOS-L), also known as B7-related protein-1 (B7RP-1), which is expressed constitutively on Bcells.
登录注册_365YUNHRTRANSLATE THIS PAGE 公司名称不能为空! 用户名不能为空! 密码不能为空!* English
* 简体
* 繁體中文
* 日本語
General Contact
__
* About
__
* Company
* Mission & Vision
* What We Do
* Leadership Team
* About JSR Life Sciences * Scientific Advisors * Strategic Partners* Careers
* News
* CVMD
__
* Menu Column 1
__
* Cardiovascular Disease__
* NHP Models
* Rodent Models
* Diabetes
__
* NHP Models
* Rodent Models
* Obesity
__
* NHP Models
* Rodent Models
* Menu Column 2
__
* NAFLD/NASH
__
* NHP Models
* MS-NASH (FATZO)
* Liver Fibrosis
__
* Rodent Models
* Renal Disease
__
* NHP Models
* Rodent Models
* Menu Column 3
__
* Safety/Toxicology
__
* Bioanalysis
* Clinical Chemistry and Biomarkers* _In Vivo_ PK/PD
* Non-GLP Toxicology * Safety Pharmacology * Biomarker Assay Services__
* Cytokine and Chemokine Profiling* Flow Cytometry
* Genomics Services
* Histology and Digital Pathology * Rare Cell Analysis* Oncology
__
* Menu Column 1
__
* _In Vivo_ Services__
* Breast Cancer Preclinical Models * Cell Line Derived Xenograft Models * Cell Line and Model Authentication * Custom Tumor Model Development * Immuno-Oncology Models* MuScreen
* Orthotopic and Bioluminescent Models * Patient-Derived Xenograft Models (HuPrime/HuKemia) * Prostate Cancer Preclinical Models* Radiation Therapy
* Syngeneic Tumor Models* Menu Column 2
__
* _In Vitro_ Services__
* Cell Based Screening__
* CrownSyn
* Cell Line and Model Authentication* Cell Line Panels
* Flow Cytometry Platform* Immuno-Oncology
* OmniScreen Cell Based Screening Service * PDX-Derived Cell Lines* Organoids
__
* Cell Line and Model Authentication * Organoid and ImmuneCell Co-Culture
* _Ex Vivo_ Services__
* 3D Assays
* Tumor Microarrays
* Menu Column 3
__
* Immuno-Oncology
__
* CAR-T Cell Therapy Models* Humanized Models
__
* Hematopoietic Stem Cell (HSC)-PDX* MiXeno
* Human Target Knock-In Models__
* HuGEMM
* HuCELL
* Murine Immunity Models and Services__
* Tumor Homograft Models * Syngeneic Tumor Models* MuScreen
* Biomarker Discovery and CDx__
* Biomarkers of Response (HuMark) * Mouse Clinical Trials (HuTrial) * Signatures of Response (HuSignature)* Menu Column 4
__
* Biomarker Assay Services__
* Cytokine and Chemokine Profiling* Flow Cytometry
* Genomics Services
* Histology and Digital Pathology * Rare Cell Analysis* Bioinformatics
__
* CrownSyn
* Pharmacology and Bioanalytical Services__
* ADME & Physicochem * Bioanalysis Studies* _In Vivo_ PK/PD
* NHP Immuno-Safety
* Structural Biology* Target Validation
* Oncology Databases__
* HuBase
* OrganoidBase
* MuBase
* Onco_Express_
* XenoBase
* Inflammation
__
* Menu Column 1
__
* _In Vivo_ Models
__
* Inflammatory Bowel Disease (IBD) * Rheumatoid Arthritis (RA)* Menu Column 2
__
* Biomarker Assay Services__
* Cytokine and Chemokine Profiling* Flow Cytometry
* Genomics Services
* Histology and Digital Pathology * Rare Cell Analysis__
* Models
__
* Cell Line Derived Xenograft * HSC and PBMC Humanized * Human Target Knock-In ( HuGEMMTM ) * Patient-Derived Xenograft ( HuPrimeTM )* Syngeneic
* Tumor Homograft ( MuPrimeTM )* Resources
__
* Posters
* Publications
* Presentations
* White Papers
* On-Demand Webinars* Events
* Quick Facts
* FactSheets
* Application Notes
* Blog
* Databases
__
* Onco_Express_
* HuBase
* OrganoidBase
* XenoBase
* MuBase
Search
* Site Search 360
* Call
__
* About
__
* Company
* Mission & Vision
* What We Do
* Leadership Team
* About JSR Life Sciences * Scientific Advisors * Strategic Partners* News
* CVMD
__
* Cardiovascular Disease__
* NHP Models
* Rodent Models
* Diabetes
__
* NHP Models
* Rodent Models
* Obesity
__
* NHP Models
* Rodent Models
* NAFLD/NASH
__
* NHP Models
* MS-NASH (FATZO)
* Liver Fibrosis
__
* Rodent Models
* Renal Disease
__
*
* NHP Models
* Rodent Models
* Safety/Toxicology
__
* Bioanalysis
* Clinical Chemistry and Biomarkers* _In Vivo_ PK/PD
* Non-GLP Toxicology * Safety Pharmacology* Oncology
__
* _In Vivo_ Services__
* Breast Cancer Preclinical Models * Cell Line Derived Xenograft Models * Cell Line and Model Authentication * Custom Tumor Model Development * Immuno-Oncology Models* MuScreen
* Orthotopic and Bioluminescent Models * Patient-Derived Xenograft Models * Prostate Cancer Preclinical Models* Radiation Therapy
* Syngeneic Tumor Models * _In Vitro_ Services__
* Cell Based Screening__
* CrownSyn
* Cell Line and Model Authentication* Cell Line Panels
* Flow Cytometry Platform* Immuno-Oncology
* OmniScreen Cell Based Screening Service * PDX Derived Cell Lines* Organoids
__
* Cell Line and Model Authentication * Organoid and Immune Cell Co-Culture * _Ex Vivo_ Services__
* 3D Assays
* Tumor Microarrays
* Immuno-Oncology
__
* CAR-T Cell Therapy Models* Humanized Models
__
* Hematopoietic stem cell (HSC)-PDX* HuGEMM
* HuCELL
* MiXeno
* Murine Immunity Models and Services__
* Tumor Homograft Models * Syngeneic Tumor Models* MuScreen
* Biomarker Discovery and CDx__
* Biomarkers of Response (HuMark) * Mouse Clinical Trials (HuTrial) * Signatures of Response (HuSignature) * Biomarker Assay Services__
* Cytokine and Chemokine Profiling* Flow Cytometry
* Genomics Services
* Histology and Digital Pathology * Rare Cell Analysis* Bioinformatics
__
* CrownSyn
* Pharmacology and Bioanalytical Services__
* ADME & Physiochem
* Bioanalysis Studies * Flow Cytometry Platform* _In Vivo_ PK/PD
* NHP Immuno-Safety
* Structural Biology* Target Validation
* Oncology Databases__
* HuBase
* OrganoidBase
* MuBase
* Onco_Express_
* XenoBase
* Inflammation
__
* _In Vivo_ Models
__
* Inflammatory Bowel Disease * Rheumatoid Arthritis (RA) * Biomarker Servicers__
* Cytokine and Chemokine Profiling * Flow Cytometry Platform* Genomics Services
* Histology and Digital Pathology Platform * Rare Cell Analysis* Models
__
* Cell Line Derived Xenograft * HSC and PBMC Humanized * Human Target Knock-In ( HuGEMMTM ) * Patient-Derived Xenograft ( HuPrimeTM )* Syngeneic
* Tumor Homograft ( MuPrimeTM )* Resources
__
* Posters
* Publications
* Presentations
* White Papers
* On-Demand Webinars* Events
* Quick Facts
* FactSheets
* Application Notes
* Blog
* Databases
__
* Onco_Express_
* HuBase
* OrganoidBase
* XenoBase
* MuBase
* Contact
x
WEBINAR: EFFICACY AND IRAE ASSESSMENT OF THERAPEUTIC ANTIBODIES WITH TARGET SPECIFIC KNOCK-IN MODELS NOVEMBER 24TH 2020 - 9AM/4PM EST Join Dr Hongjuan Zhang to learn how novel HuGEMM™ and HuCELL™ human knock-in models are used to assess human-specific immunotherapies. Explore the latest research applying these platforms to evaluating immune related toxicities, to accelerate immuno-oncology drug discovery programs. VIRTUAL US SYMPOSIUM: CLINICALLY-RELEVANT TUMOR MODELS FOR CANCER DRUG DISCOVERY AND DEVELOPMENT DECEMBER 9TH 2020 - 9AM PST Join our Virtual Symposium to learn more about using advanced, clinically-relevant models to accelerate oncology drug development. Explore the role of modeling clinical resistance when developing new anticancer agents, how to use tumor organoids to evaluate CAR-T cell therapies, the latest breakthroughs in humanized mouse models, andmore.
NEW WHITE PAPER: LEARN WHEN AND HOW TO USE TUMOR ORGANOIDS IN ONCOLOGYDRUG DISCOVERY
Learn how to select the right _in vitro_ platform for each stage of your drug development program based on model features, benefits, and limitations. Explore the optimal applications of tumor organoids, a superior and predictive research system for oncology drug development, and how to best utilize them alongside conventional platforms. ON DEMAND WEBINAR: SHIFTING THE PARADIGM OF CANCER TREATMENT: HOW CAN OPTICAL IMAGING HELP? Join Dr Yinfei Yin to explore the benefits of optical imaging in preclinical oncology research with an emphasis on immunotherapy development. Learn how imaging improves the predictive power of preclinical studies, and allows a more efficient and cost-effective translation into the clinic. Key new imaging models for evaluating novel anticancer agents will also be discussed. KEEPING YOUR PROJECTS MOVING DURING THECOVID-19 PANDEMIC
Read the update from Dr. Jean-Pierre Wery, CEO on how we're balancing our operations while keeping our staff and facilities safe. Find out more about our current global capacity - with all China sites fully operational, and a Proxy SD system for EU/US affected areas ON DEMAND WEBINAR: NEXT GENERATION SYNGENEIC MODELS TO FACILITATE IMMUNO-ONCOLOGY RESEARCH Join Dr Davy Ouyang to discover the latest cutting edge syngeneic research driving immuno-oncology development. Learn more about deep kinetic profiling, and how immune cell depletion studies are used to explore mediation of immunotherapy response. Engineered and bioluminescent syngeneics will also be discussed, as well as novel I/O platforms for moving beyond standard syngeneic studies. NEW PUBLICATION: GENOMIC ANALYSIS OF CLINICAL CHINESE CCRCC SAMPLES TO GUIDE PATIENT STRATIFICATION Explore whole-transcriptomic analysis of tumor and matched normal tissues from Chinese ccRCC patients, to investigate differences in expression profiles across Chinese and Caucasian populations. Discover how genomic analysis of clinical samples has the potential to guide patient stratification. WHITE PAPER: OPTIMIZING TRANSLATIONAL IBD CAPABILITIES HOW TO SELECT THE RIGHT PRECLINICAL MODEL Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.PRODUCTS
READY TO SHIP _IN VIVO_ AND _IN VITRO_ REAGENTS HUPRIME® Patient-Derived Xenografts (PDX) LEARN ABOUT CROWNBIO'S HUPRIME SERVICE IMMUNO-ONCOLOGY Syngeneic Tumor Models LEARN ABOUT SYNGENEIC TUMOR MODELSCVMD
MODELS OF OBESITY
CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.Learn More
Oncology
ONCOLOGY DATABASES
Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.Learn More
CVMD
DIABETES MODELS
Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for _in vivo_ efficacy studies of antidiabetic agents.Learn More
LATEST FROM OUR BLOGNovember 10, 2020
SHP2 AND SOS1 TARGETS: ADDITIONAL PLAYERS IN THE KRAS INHIBITORS RACE? Explore why upstream KRAS-mutant targets, such as SHP2 and SOS1, may lead to optimized therapeutic combinations for KRAS-mutated cancers.Read More
November 6, 2020
IN VIVO IMAGING OF SYNGENEIC MODELS FOR IMMUNO-ONCOLOGY STUDIES Explore how different imaging modalities are used to monitor in vivo immuno-oncology (I/O)...Read More
October 28, 2020
THERMONEUTRALITY AND PRECLINICAL OBESITY MODELS Explore how to improve translatability of preclinical obesity researchby using murine...
Read More
October 26, 2020
APPLICATIONS AND BENEFITS OF ENGINEERED SYNGENEIC CELL LINES Explore the use and main benefits of engineered syngeneic cell lines for investigating drug...Read More
October 21, 2020
MEET THE CROWNBIO TEAM: DR MARRIT PUTKER, ORGANOID RESEARCH SCIENTIST Meet the newest member of CrownBio’s organoid team, Marrit Putker, heading up research at our...Read More
UPCOMING EVENTS
-------------------------November 24, 2020
EFFICACY AND IRAE ASSESSMENT OF THERAPEUTIC ANTIBODIES WITH TARGET SPECIFIC KNOCK-IN MODELSVirtual
Register Now
-------------------------December 1-3, 2020
PREDICT: 9TH TUMOUR MODELS LONDONVirtual
www.tumour-models.com ------------------------- December 9th 2020 - 9am PST CLINICALLY-RELEVANT TUMOR MODELS FOR CANCER DRUG DISCOVERY AND DEVELOPMENT VIRTUAL US SYMPOSIUMVirtual
Register Now
------------------------- December 15-18, 2020 4TH ANNUAL NASH SUMMITVirtual
www.nash-summit.com
CORPORATE
* About Us
* Careers
* Investors - Investor relations* Leadership Team
* About JSR Life Sciences * Scientific Advisors * Strategic Partners* Mission & Vision
* What we do
* News
* Resources
* Blog
MODELS
* Cell Line Derived Xenograft * HSC and PBMC Humanized * Human Target Knock-In ( HuGEMMTM ) * Patient-Derived Xenograft ( HuPrimeTM )* Syngeneic
* Tumor Homograft ( MuPrimeTM )INFLAMMATION
_IN VIVO_ MODELS
* Inflammatory Bowel Disease (IBD) * Rheumatoid Arthritis (RA)BIOMARKER SERVICES
* Flow Cytometry Platform * Histology and Digital Pathology PlatformCVMD
HOME
CARDIOVASCULAR DISEASE* NHP
* Rodent
DIABETES
* NHP
* Rodent
OBESITY
* NHP
* Rodent
NAFLD/NASH
* NHP
* MS-NASH (FATZO)
LIVER FIBROSIS
* Rodent Models
RENAL DISEASE
* NHP
* Rodent
SAFETY/TOXICOLOGY
* Non-GLP Toxicology * Safety PharmacologyONCOLOGY
_IN VIVO_ SERVICES
* Breast Cancer Preclinical Models * Cell Line Derived Xenograft Models * Cell Line and Model Authentication * Custom Tumor Model Development * Immuno-Oncology Model* MuScreen
* Orthotopic and Bioluminescent Models * Patient-Derived Xenograft Models (HuPrime/HuKemia) * Prostate Cancer Preclinical Model* Radiation Therapy
* Syngeneic Tumor Models_IN VITRO_ SERVICES
* Cell Based Screening* CrownSyn
* Cell Line and Model Authentication* Cell Line Panels
* Flow Cytometry Platform* Immuno-Oncology
* OmniScreen Cell Based Screening Service * PDX-Derived Cell LinesORGANOIDS
* Cell Line and Model Authentication * Organoid and Immune Cell Co-Culture_EX VIVO_ SERVICES
* 3D Assays
* Tumor Microarrays
IMMUNO-ONCOLOGY
* CAR-T Cell Therapy Models* Humanized Models
* Hematopoietic Stem Cell (HSC)-PDX* MiXeno
* Human Target Knock-In Models* HuGEMM
* HuCELL
* Murine Immunity Model and Services* Tumor Homograft
* Syngeneic tumor
* MuScreen
ONCOLOGY
BIOMARKER DISCOVERY AND CDX * Biomarkers of Response (HuMark) * Mouse Clinical Trials (HuTrial) * Signatures of Response (HuSignature) BIOMARKER ASSAY SERVICES * Cytokine and Chemokine Profiling* Flow Cytometry
* Genomics Services
* Histology and Digital Pathology * Rare Cell AnalysisBIOINFORMATICS
* CrownSyn
PHARMACOLOGY AND BIOANALYTICAL SERVICES * ADME & Physicochem * Bioanalysis Studies* FACS Platform
* _In Vivo_ PK/PD
* NHP Immuno-Safety
* Structural Biology* Target Validation
ONCOLOGY DATABASES
* HuBase
* OrganoidBase
* MuBase
* Onco_Express_
* XenoBase
FOLLOW US
* © 2020 Crown Bioscience Inc.* Contact Us
* Site Map
* Terms of Use
* Ordering Terms
* Privacy Policy
* © 2019 Crown Bioscience Inc.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0